Lupin has entered into a definitive agreement to sell its entire stake in Japanese subsidiary Kyowa Pharmaceutical Industry Co. to Plutus Ltd for an enterprise value of 57.36 billion yen, or ₹3,702 crore. The Mumbai-based drugmaker will get 32.6 billion yen, or ₹2,104 crore, in cash from the sale of a 99.82% stake in the subsidiary to Plutus, an entity affiliated to Unison Capital, a Japan-based private equity firm, the company said in a filing with the exchanges.

— Mint

AZB & Partners advised Lupin Limited led by a team of partners Shameek Chaudhuri and Arvind Ramesh, and senior associate Rutunjay Singh.

2019-11-11

Deal value: Rs 2,104 crore

This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.